Patients
´
characteristics in mCRPC trials
PREVAIL
(Enzalutamide)
COU‐AA‐302
(Abiraterone)
TAX 327
(Docetaxel)
ALSYMPCA
(Radium‐223)
IMPACT
(Sipuleucel‐T)
Patients
characterists
Asymtomatic or
Minimally
Asymtomatic or
Minimally
Asymtomatic or
Symtomatic
Symptomatic
Asymtomatic or
Minimally
ECOG
0‐1
0‐1
0‐2 (IK 60%)
0‐2
0‐2
Older (>75 y)
35%
34%
20%
28%
NA
BPI
≤3
≤3
Any
Symptomatic
≤3
Visceral disease
Allowed
Excluded
Allowed
Excluded
Excluded
Blood Pressure
<170/105
<160/95
NA
NA
NA
Heart Failure
Excluded
NYHA 3,4
NYHA 2,3,4
NA
NA
NA
Atrial fibrillation
Allowed
Excluded
Allowed
Allowed
Allowed
